World Therapy: Nocturia – Pipeline Review, H1 2012

• Publication date: April 2012

This report provides data on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nocturia. 'Nocturia - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations an...

This report provides data on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nocturia. 'Nocturia - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Nocturia.
- A review of the Nocturia products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nocturia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Nocturia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Nocturia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Therapy Industry

Table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global March kets Direct Report Coverage 5
Nocturia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Nocturia 7
Nocturia Therapeutics under Development by Firms 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Nocturia Therapeutics – Products under Development by Firms 13
Companies Involved in Nocturia Therapeutics Development 14
Allergan, Inc. 14
Astellas Pharma Inc. 15
Urigen Pharmaceuticals, Inc. 16
Vantia Therapeutics 17
Nocturia – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
ASP7035 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
URG301 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SER120 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
VA106483 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Nocturia Therapeutics - Dormant Products 27
Nocturia – Product Development Milestones 28
Featured News & Press Releases 28
February 02, 2010: Vantia Therapeutics Initiates Phase IIb Clinical Trial Of VA106483 For Nocturia 28
June 29, 2009: Vantia Therapeutics’ Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect In Phase IIa Trial In Nocturia 28
March 24, 2009: Vantia Therapeutics' VA106483 Completes Phase IIa Trial 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables

Number of Products Under Development for Nocturia, H1 2012 7
Products under Development for Nocturia – Comparative Analysis, H1 2012 8
Number of Products under Development by Firms, H1 2012 9
Comparative Analysis by Late Stage Development, H1 2012 10
Comparative Analysis by Mid Clinical Stage Development, H1 2012 11
Comparative Analysis by Early Clinical Stage Development, H1 2012 12
Products under Development by Firms, H1 2012 13
Allergan, Inc., H1 2012 14
Astellas Pharma Inc., H1 2012 15
Urigen Pharmaceuticals, Inc., H1 2012 16
Vantia Therapeutics, H1 2012 17
Assessment by Monotherapy Products, H1 2012 18
Assessment by Stage and Route of Administration, H1 2012 20
Assessment by Stage and Molecule Type, H1 2012 22
Nocturia Therapeutics – Dormant Products 27

List of Figures

Number of Products under Development for Nocturia, H1 2012 7
Products under Development for Nocturia – Comparative Analysis, H1 2012 8
Products under Development by Firms, H1 2012 9
Late Stage Products, H1 2012 10
Mid Clinical Stage Products, H1 2012 11
Early Clinical Stage Products, H1 2012 12
Assessment by Monotherapy Products, H1 2012 18
Assessment by Route of Administration, H1 2012 19
Assessment by Stage and Route of Administration, H1 2012 20
Assessment by Molecule Type, H1 2012 21
Assessment by Stage and Molecule Type, H1 2012 22